ERBB2 and breast carcinoma: A 2011 study in Malaysia found that only 19% of 172 patients younger than 70 years with HER-2-positive breast cancer stage I to III received trastuzumab within 1 year of diagnosis, which the authors attributed to its high cost and insufficient public funding for the treatment.21